JP2019508032A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019508032A5 JP2019508032A5 JP2018539138A JP2018539138A JP2019508032A5 JP 2019508032 A5 JP2019508032 A5 JP 2019508032A5 JP 2018539138 A JP2018539138 A JP 2018539138A JP 2018539138 A JP2018539138 A JP 2018539138A JP 2019508032 A5 JP2019508032 A5 JP 2019508032A5
- Authority
- JP
- Japan
- Prior art keywords
- dcc
- somatic
- pharmaceutical composition
- cancerous disease
- mutation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims description 29
- 201000010099 disease Diseases 0.000 claims description 25
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 25
- 230000035772 mutation Effects 0.000 claims description 24
- 239000008194 pharmaceutical composition Substances 0.000 claims description 23
- 230000000392 somatic effect Effects 0.000 claims description 20
- 210000004027 cell Anatomy 0.000 claims description 16
- 101000984753 Homo sapiens Serine/threonine-protein kinase B-raf Proteins 0.000 claims description 12
- 102100027103 Serine/threonine-protein kinase B-raf Human genes 0.000 claims description 12
- 210000000349 chromosome Anatomy 0.000 claims description 12
- 102100039788 GTPase NRas Human genes 0.000 claims description 8
- 101000744505 Homo sapiens GTPase NRas Proteins 0.000 claims description 8
- 206010027476 Metastases Diseases 0.000 claims description 8
- 230000004075 alteration Effects 0.000 claims description 8
- 210000001165 lymph node Anatomy 0.000 claims description 8
- 230000009401 metastasis Effects 0.000 claims description 8
- 210000001082 somatic cell Anatomy 0.000 claims description 8
- 201000001441 melanoma Diseases 0.000 claims description 7
- 206010028980 Neoplasm Diseases 0.000 claims description 6
- 229940125431 BRAF inhibitor Drugs 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 4
- 230000035755 proliferation Effects 0.000 claims description 4
- 208000015891 sexual disease Diseases 0.000 claims description 3
- 238000002560 therapeutic procedure Methods 0.000 claims description 3
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 claims description 2
- 239000005511 L01XE05 - Sorafenib Substances 0.000 claims description 2
- 210000005005 sentinel lymph node Anatomy 0.000 claims description 2
- 229960003787 sorafenib Drugs 0.000 claims description 2
- GPXBXXGIAQBQNI-UHFFFAOYSA-N vemurafenib Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=CC(=CN=C3NC=2)C=2C=CC(Cl)=CC=2)=C1F GPXBXXGIAQBQNI-UHFFFAOYSA-N 0.000 claims description 2
- 229960003862 vemurafenib Drugs 0.000 claims description 2
- 238000009098 adjuvant therapy Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000005746 immune checkpoint blockade Effects 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000009266 disease activity Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 238000013517 stratification Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16152883.1A EP3199641B1 (en) | 2016-01-27 | 2016-01-27 | Means and methods for staging, typing and treating a cancerous disease |
| EP16152883.1 | 2016-01-27 | ||
| PCT/EP2017/051789 WO2017129753A1 (en) | 2016-01-27 | 2017-01-27 | Means and methods for staging, typing and treating a cancerous disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019508032A JP2019508032A (ja) | 2019-03-28 |
| JP2019508032A5 true JP2019508032A5 (cg-RX-API-DMAC7.html) | 2020-03-05 |
Family
ID=55310656
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018539138A Pending JP2019508032A (ja) | 2016-01-27 | 2017-01-27 | がん性疾患をステージング、タイピングおよび処置するための手段および方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US11702701B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP3199641B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2019508032A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20180102674A (cg-RX-API-DMAC7.html) |
| CN (1) | CN108770360B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2017211976B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3012404A1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2905208T3 (cg-RX-API-DMAC7.html) |
| SG (1) | SG11201805990XA (cg-RX-API-DMAC7.html) |
| WO (1) | WO2017129753A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11040027B2 (en) | 2017-01-17 | 2021-06-22 | Heparegenix Gmbh | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69900949T2 (de) | 1998-09-18 | 2002-10-02 | Micromet Ag | Dns amplifizierung aus einzelnen zellen |
| AU2002216009A1 (en) * | 2000-11-03 | 2002-05-15 | Michael Giesing | Clinical and functional validation of targets from disseminated cancer cells |
| ITRM20110149A1 (it) * | 2011-03-25 | 2012-09-26 | Massimo Zollo | Biomarcatore per la rilevazione di cellule tumorali circolanti e relativi metodi e kit di rilevazione. |
| WO2013009632A2 (en) * | 2011-07-08 | 2013-01-17 | The University Of Utah Research Foundation | Methods of detecting hereditary cancer predisposition |
| US20130149704A1 (en) * | 2011-12-10 | 2013-06-13 | Abbott Molecular Inc. | Materials and methods for diagnosis of malignant melanoma and prognosis of metastasis of malignant melanoma |
| WO2015023553A2 (en) * | 2013-08-13 | 2015-02-19 | Bionumerik Pharmaceuticals, Inc. | Contemporaneous, heterogeneously-oriented, multi-targeted therapeutic modification and/or modulation of disease by administration of sulfur- containing, amino acid-specific small molecules |
| MX2016010100A (es) | 2014-02-05 | 2016-10-07 | Fraunhofer Ges Forschung | Secuenciacion libre de error de acido desoxirribonucleico (adn). |
-
2016
- 2016-01-27 ES ES16152883T patent/ES2905208T3/es active Active
- 2016-01-27 EP EP16152883.1A patent/EP3199641B1/en active Active
-
2017
- 2017-01-27 AU AU2017211976A patent/AU2017211976B2/en active Active
- 2017-01-27 WO PCT/EP2017/051789 patent/WO2017129753A1/en not_active Ceased
- 2017-01-27 CN CN201780008861.6A patent/CN108770360B/zh active Active
- 2017-01-27 CA CA3012404A patent/CA3012404A1/en active Pending
- 2017-01-27 JP JP2018539138A patent/JP2019508032A/ja active Pending
- 2017-01-27 EP EP17706412.8A patent/EP3408411A1/en not_active Withdrawn
- 2017-01-27 US US16/073,271 patent/US11702701B2/en active Active
- 2017-01-27 SG SG11201805990XA patent/SG11201805990XA/en unknown
- 2017-01-27 KR KR1020187024606A patent/KR20180102674A/ko active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Klapp et al. | The DNA damage response and inflammation in cancer | |
| Pitroda et al. | Integration of radiotherapy and immunotherapy for treatment of oligometastases | |
| Wick et al. | N2M2 (NOA-20) phase I/II trial of molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed non-MGMT hypermethylated glioblastoma | |
| Aung et al. | Genomics-driven precision medicine for advanced pancreatic cancer: early results from the COMPASS trial | |
| Litvak et al. | Clinical characteristics and course of 63 patients with BRAF mutant lung cancers | |
| Cho et al. | Nilotinib in patients with metastatic melanoma harboring KIT gene aberration | |
| Youngblood et al. | Acquired transcriptional programming in functional and exhausted virus-specific CD8 T cells | |
| JP2018508469A5 (cg-RX-API-DMAC7.html) | ||
| ES2686549T3 (es) | Método para seleccionar una triterapia personalizada para el tratamiento del cáncer | |
| JP2018532736A5 (cg-RX-API-DMAC7.html) | ||
| IL294183B2 (en) | shared neoantigens | |
| JP2018513155A5 (cg-RX-API-DMAC7.html) | ||
| Lu et al. | Prognostic advantage of irinotecan dose escalation according to uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) genotyping in patients with metastatic colorectal cancer treated with bevacizumab combined with 5-fluorouracil/leucovorin with irinotecan in a first-line setting | |
| Remon et al. | How to optimize the incorporation of immunotherapy in trials for oligometastatic non-small cell lung cancer: a narrative review | |
| JP2020520923A5 (cg-RX-API-DMAC7.html) | ||
| Sawamura et al. | Crizotinib-associated erythema multiforme in a lung cancer patient | |
| Yang et al. | Enhanced antitumor effects of radiotherapy combined local nimustine delivery rendezvousing with oral temozolomide chemotherapy in glioblastoma patients | |
| Meng et al. | Treatment advances in lung cancer with leptomeningeal metastasis | |
| JP2019508032A5 (cg-RX-API-DMAC7.html) | ||
| US20210085745A1 (en) | Methods of identifying risk of bevacizumab-induced proteinuria and hypertension | |
| Li et al. | Targeting BRCA‐mutant biliary tract cancer: Current evidence and future perspectives | |
| Andrews et al. | Outcomes following cytoreductive nephrectomy without immediate postoperative systemic therapy for patients with synchronous metastatic renal cell carcinoma | |
| Li et al. | The recent progress of tumor cell-derived exosomes in the pathogenesis, diagnosis and therapeutic strategies of tumors | |
| Flippot et al. | Management of metastatic renal cell carcinoma with variant histologies | |
| Kenneth | Advances in systemic therapy in pancreatic cancer |